Barbara Tilley to Tissue Plasminogen Activator
This is a "connection" page, showing publications Barbara Tilley has written about Tissue Plasminogen Activator.
Connection Strength
1.249
-
Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke. 1998 Aug; 29(8):1504-9.
Score: 0.124
-
Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Arch Neurol. 1997 Dec; 54(12):1466-74.
Score: 0.119
-
Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. Ann Emerg Med. 1997 Nov; 30(5):676-82.
Score: 0.118
-
Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke. 1996 Nov; 27(11):2136-42.
Score: 0.110
-
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014 Nov 29; 384(9958):1929-35.
Score: 0.094
-
Application of beta regression to analyze ischemic stroke volume in NINDS rt-PA clinical trials. Neuroepidemiology. 2011; 37(2):73-82.
Score: 0.077
-
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010 May 15; 375(9727):1695-703.
Score: 0.070
-
Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke. 2006 Oct; 37(10):2508-13.
Score: 0.054
-
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke. 2006 Jul; 37(7):1798-804.
Score: 0.054
-
The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Ann Emerg Med. 2005 Apr; 45(4):377-84.
Score: 0.049
-
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 Mar 06; 363(9411):768-74.
Score: 0.046
-
Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial. Neurology. 2003 Oct 28; 61(8):1158-9.
Score: 0.045
-
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002 Sep 10; 59(5):669-74.
Score: 0.041
-
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001 Dec 12; 286(22):2830-8.
Score: 0.039
-
Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000 Dec 12; 55(11):1649-55.
Score: 0.037
-
Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke. 2000 Oct; 31(10):2335-41.
Score: 0.036
-
Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke. 1999 Aug; 30(8):1528-33.
Score: 0.033
-
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999 Jun 10; 340(23):1781-7.
Score: 0.033
-
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998 Apr; 50(4):883-90.
Score: 0.030
-
Benefits of stroke treatment delivered using a mobile stroke unit trial. Int J Stroke. 2018 04; 13(3):321-327.
Score: 0.029
-
Use of odds ratio or relative risk to measure a treatment effect in clinical trials with multiple correlated binary outcomes: data from the NINDS t-PA stroke trial. Stat Med. 2001 Jul 15; 20(13):1891-901.
Score: 0.010